Business Context and Reporting Period
Company: ImmunityBio, Inc. (IBRX)
Filing Type: Form 8-K (Current Report)
Date of Report: February 18, 2026
Event: Item 8.01 Other Events – Regulatory Authorization
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a regulatory milestone and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the receipt of authorization from the European Commission for the Company's product, ANKTIVA® with BCG, for the treatment of Non-Muscle Invasive Bladder Cancer Carcinoma in Situ. This authorization expands the global access of the product to 33 countries.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the European Commission authorization but does not include specific forward-looking guidance, financial outlook, or detailed risk factors within the body of this 8-K text.
Unusual Items: None reported in this specific filing text.
Investor Verification Checklist
- Verify the specific commercial terms and launch timeline for ANKTIVA® with BCG in the 33 newly accessible European countries.
- Review the attached press release (Exhibit 99.1) for detailed clinical data supporting the authorization.
- Assess the potential revenue impact of this expansion against the Company's current financial position in subsequent quarterly filings (10-Q/10-K).
- Confirm any pricing strategies or reimbursement approvals associated with the European Commission authorization.